OTCMKTS:CWBR
CohBar Inc Stock News
$0.88
+0 (+0%)
At Close: May 17, 2024
CohBar to Announce 2020 Fourth Quarter Financial Results and Provide Business Update on March 30, 2021
04:05pm, Tuesday, 16'th Mar 2021
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
CohBar to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
09:00am, Friday, 12'th Mar 2021
MENLO PARK, Calif., March 12, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exte
CohBar to Present at the 33rd Annual ROTH Conference
09:00am, Tuesday, 02'nd Mar 2021
MENLO PARK, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exte
CohBar to Present at the BIO CEO & Investor Digital Conference
09:00am, Tuesday, 09'th Feb 2021
MENLO PARK, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exten
CohBar to Present at the 3rd Annual Longevity Therapeutics Conference
09:00am, Wednesday, 20'th Jan 2021
MENLO PARK, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exten
CohBar Confirms Efficacy of Novel Apelin Agonists in Acute Respiratory Distress Syndrome (ARDS) Model
09:00am, Wednesday, 09'th Dec 2020
MENLO PARK, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exten
CohBar to Present at the Piper Sandler 32nd Annual Healthcare Conference
09:00am, Thursday, 19'th Nov 2020
MENLO PARK, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exten
CohBar, Inc. (CWBR) CEO Steve Engle on Q3 2020 Results - Earnings Call Transcript
01:46pm, Tuesday, 17'th Nov 2020
CohBar, Inc. (CWBR) CEO Steve Engle on Q3 2020 Results - Earnings Call Transcript
CohBar Reports Third Quarter 2020 Financial Results and Provides Business Update
04:01pm, Monday, 16'th Nov 2020
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
CohBar to Announce 2020 Third Quarter Financial Results and Provide Business Update on November 16, 2020
09:00am, Monday, 02'nd Nov 2020
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
CohBar to Host Key Opinion Leader Meeting on Antifibrotic Peptides for the Potential Treatment of Idiopathic Pulmonary Fibrosis
09:00am, Thursday, 29'th Oct 2020
MENLO PARK, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exten
CohBar to Participate at ROTH Capital COVID-19 Therapeutics in Development Event
09:00am, Tuesday, 27'th Oct 2020
MENLO PARK, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exten
CohBar Antifibrotic Peptide in Combination with Nintedanib Shows Enhanced Effects in an Idiopathic Pulmonary Fibrosis Model
09:00am, Monday, 26'th Oct 2020
Company to host a Key Opinion Leader webinar on the current treatment landscape in IPF, the unmet need, and positive findings from preclinical studies of CohBar's CB5138 Analogs on Friday, November 6
Tricida Suffers Setback, And Other News: The Good, Bad And Ugly Of Biopharma
01:43am, Wednesday, 26'th Aug 2020
Tricida suffers setback on Veverimer front. CohBar advances its Phase 1b trial for NASH treatment.
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.30%
12:00am, Wednesday, 26'th Aug 2020
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.30%
